Based on the target pathways of CD19+ B cells and CD4+ T cells in Fingolimod for MS and pDCs and PBMCs in IFN-β for MS, we can know that the “PI3K-Akt signaling pathway” and the “Chemokine signaling pathway” are more important, so we focus on drugs that target these pathways simultaneously. The gene discussed is PIK3CG; the disease is myeloid sarcoma.